ZT002 Injection
DrugAdministered SC
NCT Number: NCT07020884
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Handan First Hospital, Handan, Hebei, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered SC
Administered SC
Time frame: baseline, 24 weeks
Time frame: 24 weeks
Looking for future studies?
Notify MeBeijing QL Biopharmaceutical Co.,Ltd
Industry
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Subjects With Overweight or Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06649045
Body Weight, Nutrition Disorders
Long Beach, California, United States
View Trial DetailsNCT06712836
Body Weight, Nutrition Disorders
Anaheim, California, United States
View Trial DetailsNCT06621316
Body Weight, Nutrition Disorders
Beijing, Beijing Municipality, China
View Trial DetailsNCT06854952
Body Weight, Nutrition Disorders
Birmingham, Alabama, United States
View Trial Details